Summary
In postmyocardial infarction patients longterm aspirin treatment with 1.5 g/day led to a significant increase in systolic and diastolic blood pressure after 6 months. This could not be found in the placebo- and the phenprocoumon-treated patients. After one year the blood pressure behaviour was the same in all three treatment groups. As nonsteroidal antirheumatic drugs can produce hypertension in animals, probably due to inhibition of prostaglandin synthesis, blood pressure control in longterm aspirin treatment is advisable.
Zusammenfassung
Nach 6 Monaten Therapie mit 1,5 g Acetylsalizylsäure täglich wurde bei Postinfarkt-Patienten ein signifikanter Anstieg des systolischen und diastolischen Blutdrucks beobachtet. Ein solches Ansteigen des Blutdrucks konnte bei den mit Placebo oder Phenprocoumon Behandelten nicht nachgewiesen werden. Ein Jahr nach Therapiebeginn war das Blutdruckverhalten gleich in allen drei Therapiegruppen. Da auch bei Tieren mit nichtsteroidalen Antirheumatika ein Hochdruck erzeugt werden konnte, wahrscheinlich durch Hemmung der Prostaglandinsynthese, ist die regelmäßige Blutdruckkontrolle während einer Langzeit-Aspirin-Therapie ratsam.
References
Breddin K (1968) Die Thrombocytenfunktion bei hämorrhagischen Diathesen, Thrombosen und Gefäßkrankheiten. Thromb Diath Haemorrh 27 [Suppl]
Breddin K, Überla K, Walter E (1977) German-austrian multicenter two years prospective study on the prevention of secondary myocardial infarction by ASA in comparison to phenprocoumon and placebo. Thromb Haemostas 38 (1):168 (Abstract)
Burch JW, Stanford N, Majerus PW (1978) Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 61:314–319
Colina-Chourio J, McGiff JC, Nasjletti A (1975) Development of high blood pressure following inhibition of prostaglandin synthesis. Fed Proc 34:368 (Abstract)
Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1:436–440
Elwood PC, Sweetnam PM (1979) Aspirin and secondary mortality after myocardial infarction. Lancet 2:1313–1315
Gafni Y, Schwartzman M, Raz A (1978) Prostaglandin biosynthesis in rabbit renal medulla: Inhibition in vitro vs. in vivo by aspirin, indomethacin and meclofenamic acid. Prostaglandins 15:759–772
Klimt ChR (1978) Results of the coronary drug project aspirin study and design of the aspirin myocardial infarction study and the persantine-aspirin reinfarction study. In: Breddin K, Dorndorf W, Loew D, Marx R Acetylsalicylic acid in cerebral ischemia and coronary heart disease (eds) Schattauer, Stuttgart New York, pp 129–140
Lonigro AJ, Itskovitz HD, Crowshaw K, McGiff JC (1973) Dependency of renal blood flow on prostaglandin synthesis in the dog. Circ Res 32:712–717
Masotti G, Galanti G, Poggesi L, Abbate R, Neri Serneri GG (1979) Differential inhibition of prostacyclin production and platelet aggregation by aspirin. Lancet 2:1213–1216
McGiff JC (1979) Prostaglandins in circulatory disorders. Triangel 18:101–107
Romero JC, Strong CG (1977) The effect of indomethacin blockade of prostaglandin synthesis on blood pressure of normal rabbits and rabbits with renovascular hypertension. Circ Res 40:35–41
Rosenthal J, Simon PG, Silbergleit A (1974) Effects of prostaglandin deficiency on natriuresis, diuresis, and blood pressure. Prostaglandins 5:435–440
The Coronary Drug Project (CDP) Research Group (1976) Aspirin in coronary heart disease. J Chron Dis 29:625–642
The Persantine-Aspirin Reinfarction Study (PARIS) Research Group (1980) Persantine and aspirin in coronary heart disease. Circulation 62:449–461
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Walter, E., Kaufmann, W. & Oster, P. Does chronic aspirin treatment increase blood pressure in man?. Klin Wochenschr 59, 297–299 (1981). https://doi.org/10.1007/BF01478209
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01478209